The hexosamine pathway (HP) is a biochemical hypothesis recently proposed explaining cellular alterations occurring during diabetic microvascular complications. Diabetic retinopathy is a common microvascular complication of diabetes, and it is known that cell proliferation is severely affected during the development of the disease. Particularly, early stages are characterized by death of the retinal microvascular cells, pericytes. Gangliosides have often been described to regulate cell growth, however very few studies focused on the potential role of gangliosides in diabetic microvascular alterations. The aim of the present study was to investigate the effect of the HP activation on pericyte proliferation and to determine the potential implication of gangliosides in this process. Results indicate first that HP activation, mimicked by glucosamine treatment, decreased pericyte proliferation. Second, glucosamine treatment induced a modification of gangliosides pattern, particularly, GM1 and GD3 were significantly increased. Next, results showed that exogenous addition of a-series gangliosides (GM3, GM2,GM1, GD1a) and b-series ganglioside (GD3) caused a decrease of pericyte proliferation, whereas non-sialylated precursors glucosylceramide and lactosylceramide were without effect. Further, when ganglioside biosynthesis was blocked using PPMP, a glucosylceramide synthase inhibitor, the effects of glucosamine on pericyte proliferation were partially reversed. Our results suggest that, in retinal pericytes, gangliosides and particularly GM1 and GD3 that are increased in response to glucosamine, are involved in the anti-proliferative effect of glucosamine. These observations also underlie the potential involvement of gangliosides in a pathological context, such as diabetic microvascular complications.
Introduction
Gangliosides are glycosphingolipids characterized by the presence of sialic acid in their oligosaccharidic portion. After the initial glycosylation step of ceramide catalyzed by glucosylceramide synthase, successive sialylations and glycosylations lead to a wide diversity of gangliosides. They are concentrated in plasma membranes with a cell-specific pattern.
They are found in most tissues of the body and are particularly abundant in brain and nervous tissues (van Echten et al., 1993) . Gangliosides are known to exert a bifunctional role (Hakomori, 1990) . On one hand, they play major roles in cell-cell and cell-matrix recognition via interactions with adhesion receptors such as integrins, matrix proteins (collagen and fibronectin), or with other glycosphingolipids, giving them important role in morphogenesis and oncogenesis. In addition, a number of gangliosides may act as receptors of bacteria, viruses or toxins. On the other hand, gangliosides are known to regulate transmembrane signaling by modulating functional membrane proteins. Thus, they have been described to regulate cell proliferation through modulation of growth factor receptor-associated kinases such as EGF and PDGF receptors (Bremer et al., 1986; Mirkin et al., 2002; Sachinidis et al., 1996; Van Brocklyn et al., 1993) . The importance of gangliosides in regulating cell proliferation is also supported by studies implicating them in cell cycle arrest processes via cyclin-dependent kinase inhibitors (Nakatsuji et al., 2001) or in apoptosis through mitochondrial events (Kristal et al., 1999; Rippo et al., 2000) .
It is well documented that regulation of cell proliferation is severely affected in retinopathy, a main microvascular complication of diabetes. Death of retinal pericytes, microvascular contractile cells, is indeed one of the earliest retinal changes, induced by hyperglycemia.
Pericyte loss and subsequent modification of endothelial cell proliferation and function, combined with basement membrane thickening, trigger structural and functional alterations of capillaries. These chronic alterations establish edema, microaneurisms and hemorrage that at ultimate stages can lead to blindness (Forrester J.V. et al., 1997) .
Although the pathogenic basis of diabetic microangiopathy is not fully understood at cellular and molecular levels, it is clear that regulations of cell proliferation play an important role.
The hexosamine pathway (HP), a novel glucose-sensing pathway, has been implicated in hyperglycemia-induced diabetic vascular alterations (Marshall et al., 1991) . After entering cells, glucose is rapidly phosphorylated and converted to fructose-6-phosphate (F-6-P) which is mainly catabolized through the glycolytic pathway. Nevertheless, under hyperglycemic conditions, a greater part of F-6-P can be converted to glucosamine-6-phosphate by glutamine:F-6-P amidotransferase (GFAT), the first and rate-limiting enzyme of the hexosamine biosynthetic pathway. Glucosamine-6-phosphate then undergoes rapid conversion to various hexosamine products, including UDP-N-acetylglucosamine (UDPGlcNAc). Thus, the HP can be activated under the hyperglycemic conditions of a diabetic state by increased availability of substrate (F-6-P) and/or GFAT activation. HP exerts its effects via two described mechanisms. First, hexosamine product biosynthesis provides glycosidic precursors for the synthesis of glycoproteins, glycolipids and proteoglycans. These intermediates can especially be used in the endoplasmic reticulum to form complex glycoproteins, secreted or inserted into the membrane where they can modulate transmembrane signaling or extracellular interactions. Additionally, UDP-GlcNAc can be used as precursor for CMP-sialic acid, a substrate of ganglioside biosynthesis, raising the possibility of a connection between HP and the ganglioside pathway. Second, cytosolic or nuclear proteins can be covalently modified by the addition of a single monosaccharide GlcNAc, a product of the HP. This O-linked glycosylation occurs on key intracellular proteins playing roles in controlling gene expression, cell growth and division, enzyme activity, or structural integrity of the cytoskeleton (Marshall, 2002 A growing number of studies suggest a role of HP in glucose-induced insulin resistance (Hebert, Jr. et al., 1996; Kaneto et al., 2001; Vosseller et al., 2002) and in diabetic nephropathy, particularly in renal mesangial cell alterations (Kolm-Litty et al., 1998; Schleicher et al., 2000; Singh et al., 2001) . However very few studies, if any, have examined the involvement of HP in the development of diabetic retinopathy. Moreover, although gangliosides play major role in cell proliferation, their potential involvement in diabetic microvascular complications and particularly in retinal pericyte growth perturbations has been poorly studied.
The aim of the present study was to investigate the effect of the HP activation on pericyte proliferation, ganglioside profile, and potential link between the two events. Results indicated that glucosamine modifies pericyte ganglioside pattern concomitantly to a decrease of cell proliferation. Further, addition of exogenous gangliosides exerted anti-proliferative effects on pericytes, suggesting that gangliosides are involved in mediating the adverse glucosamine effects on pericyte proliferation.
Results

Glucosamine treatment inhibits pericyte proliferation
To evaluate the effect of HP on pericyte growth, cells were treated with glucosamine which bypasses the rate limiting enzyme GFAT and mimics an exacerbation of the HP. Cells were exposed to 5mM glucosamine for 1 to 7 days and proliferation was estimated by cell counting and total proteins measurement. As shown in Figure 1 , time-course experiments revealed that glucosamine potently decreased pericyte proliferation starting at 1-2 days of treatment. Cell counting revealed that glucosamine reduced pericyte number by 32% and 40% after 2 and 7 days of treatment, respectively. A decrease of total proteins was also observed in glucosamine treated cells and correlated to cell number (Fig. 1C) . To investigate the effects of glucosamine on cell proliferation, apoptosis was measured in cells treated for 7 days with 5mM glucosamine. Measurement of caspase 3 activation and determination of DNA fragmentation using an oligonucleosomes determination kit showed that glucosamine did not induce apoptosis of bovine retinal pericytes (BRP), at least under our culture conditions (data not shown). These results suggest that the growth inhibition observed in response to glucosamine might involve cell cycle events.
Glucosamine modulates ganglioside profile
Ganglioside pattern of bovine retinal pericytes was analyzed in control and cells treated with 5mM glucosamine. Under control conditions, the main gangliosides were GM3 (60% of all gangliosides detected), GD3 (28%) and GM1 (12%) (Fig. 2A) . As shown in Figure 2 , important modifications of ganglioside profile were observed in response to glucosamine (Fig   2B-C) . Thus, GM1 and GD3 masses were increased by 27 and 19%, and by 85 and 105%, after 2 and 7 days of treatment, respectively. Conversely, GM3 mass was decreased by 21 and 32% after 2 and 7 days of treatment, respectively. Similar results were obtained by autoradiography analysis after galactose labeling (data not shown). These results suggest a possible connection between the hexosamine pathway and the ganglioside biosynthesis pathway. As the glucosamine effects were maximal at 7 days, subsequent experiments were performed at this time of treatment.
Glucosamine increases GM3 synthase activity
To investigate the mechanism responsible for the observed increase of GM1 and GD3 masses, GM3 synthase activity, a rate-limiting enzyme for the synthesis of gangliosides was measured in control and treated cells. Results presented in Figure 3 show that glucosamine treatment increased GM3 synthase activity by about 160%. As GM3 is a precursor of complex gangliosides, its decrease despite the augmentation of GM3 synthase activity suggests that GM3 was metabolized to GM1 and GD3 that are both increased in response to glucosamine.
Treatment with exogenous gangliosides inhibits pericyte proliferation
Since GM1 and GD3 were increased concomitantly to a decrease of cell proliferation in response to glucosamine, we further explored the hypothesis that gangliosides are involved in mediating the glucosamine effects. Thus, we investigated whether the addition of exogenous gangliosides affects pericyte proliferation. Cells were treated during one passage (7 days) with 10, 50 or 100 µM gangliosides and, as a control, with the non-sialylated precursors glucosylceramide and lactosylceramide. Results presented in Figure 4 show that GM1 and GD3 inhibited pericyte proliferation in a dose-dependent manner whereas glucosylceramide and lactosylceramide used as controls showed no effects. Inhibition of cell proliferation reached 25% at ganglioside concentration of 100 µM. The effect of a-series gangliosides that were not increased in response to glucosamine was also tested. Results indicated that GM3, GM2, and GD1a also inhibited BRP proliferation (data not shown), suggesting that the presence of sialic acid is required in the active structure leading to inhibition of BRP proliferation. It should be indicated however, that treatment with exogenous gangliosides resulted in rather modest effects as compared to the effects of glucosamine. These data might be explained by the fact that only a small proportion of added gangliosides are inserted into cell membranes. Additionally, exogenous gangliosides treatment may result in the generation of cell membrane pool functionally different from the gangliosides pool formed endogenously in response to glucosamine treatment.
PPMP protects against the inhibition of proliferation caused by glucosamine
Next, a complementary approach was used to further support the involvement of gangliosides in the anti-proliferative effects of glucosamine on pericytes. PPMP, an inhibitor of glucosylceramide synthase was used to block the increase of gangliosides caused by glucosamine. As shown in Figure 5 , treatment of BRP with glucosamine in the presence of increasing concentrations of PPMP partially protected cells against proliferation decrease, in a dose-dependent manner.
Altogether, these results support the hypothesis that GM1 and GD3 increase is involved, at least in part, in the proliferation decrease of pericytes treated with glucosamine. Further, as it is known that retina expresses active GFAT and that hexosamine content is increased in retinal tissues in human and rats with diabetes (Heath et al., 1967; Mazlen et al., 1970) , this raises the hypothesis that the HP could possibly be implicated in diabetic retinopathy development and pericyte loss. On the other hand, gangliosides are known to play a role in cell differentiation and growth regulation. Altered ganglioside levels have been associated with oncogenic transformation or inherited disease such as Farber's disease (Farina et al., 2000; Manzi et al., 1990; Zeng et al., 2000) , although very little is known concerning the mechanism or the biological significance of these changes. However, ganglioside changes and their involvement in diabetes where cell growth is also altered have been poorly studied.
In the present study, ganglioside modifications and their consequences on proliferation of pericytes submitted to diabetic environment were investigated. Glucosamine, that is avidly taken up by the glucose transporter and phosphorylated by hexokinase when added to cells (Schleicher et al., 2000) , was used to mimic the high glucose environment effects that are mediated by the HP in our model. Pericytes were chosen as their growth is particularly affected in diabetic microangiopathy. Results demonstrate that glucosamine treatment induces modification of BRP ganglioside profile with an increase of GM1 and GD3 and a decrease of GM3. Moreover, glucosamine increased GM3 synthase activity, which regulates GM3 biosynthesis, a precursor of complex gangliosides. Thus, by increasing GM3 synthase activity, glucosamine could drive complex ganglioside biosynthesis. This hypothesis is supported by the observed increase of GM1 and GD3. Glucosamine regulates GM3 synthase activity through yet undefined mechanism. One possible explanation is through regulation of GM3 synthase gene expression. In fact, human GM3 synthase promoter presents putative binding sites for SP1 (Zeng et al., 2003) , a transcription factor whose activity is known to be regulated by O-linked N-acetylglucosamine modification (Goldberg et al., 2002) . On the other hand, it should be also considered that glucosamine can lead to increased ganglioside biosynthesis by providing excessive substrates that increase the flux of ganglioside biosynthesis in glucosamine-treated pericytes. Indeed, UDP-GlcNAc can be converted into CMP-sialic acid, a precursor of ganglioside biosynthesis.
Next, results showed that glucosamine causes a decrease of pericyte proliferation. This proliferation decrease is partially reproduced by the application of exogenous gangliosides including GM1 and GD3, both increased in response to glucosamine. This observation suggests a role of gangliosides in mediating glucosamine effects. Of note, previous studies have documented that only 20% of exogenously added gangliosides are inserted into cell membranes (Bremer et al., 1984) . This might explain the less potent effects of exogenous gangliosides on decreasing pericyte proliferation as compared to glucosamine. These results are in accordance with other studies showing that gangliosides can decrease cell growth, by modulating growth factor receptor signaling. For example, GM1 has been shown to inhibit epidermal growth factor and platelet-derived growth factor receptor phosphorylation and signaling in different cell types (Bremer et al., 1986; Mirkin et al., 2002; Sachinidis et al., 1996; Van Brocklyn et al., 1993) . Moreover, GD3 has been described as an intracellular mediator of apoptosis, particularly by inducing mitochondrial permeability transition, cytochrome c release and caspase activation (Garcia-Ruiz et al., 2000; Kristal et al., 1999; Rippo et al., 2000) . A complementary approach using PPMP, an inhibitor of glucosylceramide synthase, was used next. Addition of PPMP to glucosamine treatment partially protected pericytes against the proliferation decrease, supporting a role of gangliosides in mediating the glucosamine effects. These data also suggest that unknown additional pathways are also involved in causing decrease of pericyte proliferation in response 10 at Pennsylvania State University on February 21, 2013 http://glycob.oxfordjournals.org/ Downloaded from to glucosamine. As discussed earlier, the hexosamine pathway can affect cell proliferation through several pathways and mechanisms. Activation of the hexosamine pathway leads to OGlcNAc modifications of proteins such as transcription factors (Wells et al., 2001 ). For example it has been shown in bovine aortic endothelial cells that the transcription factor SP1 is modified by O-GlcNAc in response to hyperglycemia or elevated glucosamine (Du et al., 2000) . Increased O-GlcNAc modification of SP1 increases SP1 transactivation and SP1-dependent expression of TGF-β1 and PAI-1 (Du et al., 2000) . Interestingly, SP1 has also been shown to regulate the expression of proteins involved in cell cycle regulation such as p21 waf1/cip1 (Gartel et al., 1999) . As in our study, glucosamine did not inhibit BRP proliferation through apoptosis, it would be of great interest to investigate the effect of glucosamine on cell cycle proteins such as p21 waf1/cip1 in these cells.
In conclusion, the present study indicates that glucosamine increases ganglioside biosynthesis in pericytes and suggests that gangliosides are likely involved in the anti-proliferative effect of glucosamine in this cell type. These observations also indicate that the ganglioside pattern can be modified by a diabetic environment and extend the role of gangliosides into the field of diabetic microvascular complications. 
Materials and methods
Cell isolation and culture
Bovine retinal pericytes (BRP) were isolated from microvessels of bovine retinas as previously described (Lecomte et al., 1996) . Briefly, retinas were dissected under sterile conditions from freshly enucleated bovine eyes obtained from a local slaughterhouse. Retinas and cultured up to the second passage during which they were treated. Glucosamine (Sigma) was added to the culture medium at 5 mM final concentration and culture medium was replaced every two days. BRP were treated for 1 to 7 days.
Ganglioside analysis
At the end of the treatment period, pericytes 
Measurement of GM3 synthase activity
At the end of treatment, cells were washed with PBS, incubated for 20 min at 4°C in 50 µl lysis buffer (20 mM sodium cacodylate pH 6.6 (Sigma), 0.2% Triton X-100, 1 mM EDTA, 10 µl/ml proteases inhibitors, Calbiochem, Merck KGaA, Darmstadt, Germany) and then collected by scrapping. Four dishes of BRP (~2-3 × 10 6 cells) were pooled. Cell lysates were centrifuged at 10,000g for 5 min, and proteins in the supernatants were used to measure GM3 synthase activity. Equal amounts of proteins from each sample (about 500 µg) were used to perform the assay. Samples were mixed with an equal volume of reaction buffer containing at final concentrations: 0.1 mM lactosylceramide (Matreya), 4 µCi/ml [sialic-4,5,6,7,8,9- acid (Sigma), 10 mM MgCl 2 , 0.2% Triton X-100, 100 mM sodium cacodylate pH 6.6. After shaking, the reaction mixtures were incubated at 37°C for 150 min. Reactions were stopped by loading the samples on silica gel 60 columns (Merck) to separate excess of substrates from products. After washing the columns with water, gangliosides were eluted with C/M (1:1, v/v) and the solvent dried under nitrogen. Gangliosides were finally separated by TLC (Merck) and reaction products were revealed by autoradiography. GM3 synthase activity was expressed as pmoles of GM3 produced per hour/mg proteins.
Measurement of cell growth
After each treatment period, cells were harvested with trypsin and cell pellets were washed twice with PBS. For each sample, an aliquot of cells was counted using a haemocytometer to determine the cell number, another aliquot was used to measure proteins according to Bradford.
Treatment with exogenous gangliosides
To evaluate the effect of exogenous gangliosides on BRP proliferation, cells were cultured in 96 wells plates. Exogenous glycolipids GM1, GD3, glucosylceramide and lactosylceramide (Matreya) were added to the culture complete medium at final concentrations of 10, 50 or 100 µM in the form of complexes with BSA at a ratio of 1:1 in DMEM-10 mM Hepes, pH 7.4 to facilitate their incorporation within the cell. At the end of treatment, cells were washed twice with PBS and lysed for 30 min at 37°C in 50 µl Ripa lysis buffer (PBS 10 mM, NP40 1%
(Pierce, Perbio Science, Brebières, France), sodium deoxycholate 0.5%, SDS 0.1%, 10 µl/ml proteases inhibitors). Total proteins were finally measured using the BCA protein assay (Pierce) to assess cell proliferation, as in our experiments cell numbers correlated with total protein concentrations (see Fig. 1 ).
PPMP treatment
In order to inhibit ganglioside biosynthesis, DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP, Sigma), an inhibitor of glucosylceramide synthase that catalyses the first step of ganglioside biosynthesis, was used. BRP were cultured in 96 wells plates and treated with 5 mM glucosamine in the presence of increasing concentrations of PPMP for 7 days. PPMP was not used at concentrations higher than 1µM as it caused cellular morphological alterations and toxic effects. At the end of treatment, cells were washed twice with PBS, lysed in Ripa and proteins were measured to assess cell proliferation as described above.
Statistical analysis
Data are expressed as means ± SEM and presented as percentage of controls. The Wilcoxon signed-rank test was used to define the significance of the difference between groups. p< 0.05 was considered as statistically significant. Pericytes were exposed to 5 mM glucosamine for 2 (B) or 7 (C) days, and then collected.
Gangliosides were analysed by HPTLC and resorcinol staining. Representative HPTLC of gangliosides after 7 days treatment revealed by resorcinol (A) and densitometric quantification of 3-7 independent experiments (B, C) are shown. Results are expressed as µg of gangliosides per mg of proteins and represent means ± SEM. * p<0.05 vs control. Std, standard. The band on the origin was unknown, therefore it was not quantified. 
